Earnings News - Candlesense

Asetek - Q2 2025: Positioning for Future Growth

Q2 revenue of $11.2 million, compared with $12.7 million in Q2 2024. Q2 gross margin of 45%, level with Q2 2024 Q2 adjusted EBITDA of $82 thousand, compared with $239 thousand in Q2 2024 Liquid Coo...

How does Asetek's performance and growth trajectory compare to its key competitors in the liquid‑cooling market, and what market share implications might arise? What guidance or outlook is management providing for Q3 and full‑year 2025, especially regarding liquid‑cooling sales and gross margin trends? How will the decline in Q2 revenue and adjusted EBITDA affect Asetek's short‑term stock momentum and valuation multiples?

Symbol: ASET

21 days ago

CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

SHENZHEN, CHINA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025...

How does CMS's growth and margin expansion compare with its main peers in the Chinese pharmaceutical sector? What guidance or outlook does CMS provide for the full‑year 2025 performance and its strategic transformation milestones? How will the reported revenue and profit growth affect CMS's share price in the short term?

Symbol: CMS

21 days ago

Read more globenewswire

Jyske Bank’s Financial Calendar 2026

Jyske Bank anticipates releasing the following financial statements in 2026:

Symbol: JYSK

21 days ago

Read more globenewswire

Coloplast A/S - Interim Financial Report, 9M 2024/25

2024/25

What guidance or outlook does the company provide for the remainder of the fiscal year, and how might this affect the stock's valuation and momentum? How does Coloplast's interim financial results compare to market expectations and its peers in the medical device sector? What are the key drivers behind the reported revenue and earnings performance for the first 9 months of 2024/25?

Symbol: COLO

21 days ago

Read more globenewswire

Basilea on track with strong 2025 half-year results

Ad hoc announcement pursuant to Art. 53 LR

How does Basilea's performance stack up against its biotech peers, and what are the implications for relative valuation? What guidance did Basilea provide for the remainder of 2025 and FY2026, and how does it compare to market expectations? How will the strong 2025 half-year results influence BASE's short‑term price target and trading volume?

Symbol: BASE

21 days ago

Read more globenewswire

Scatec second quarter 2025: Strong financial performance with continuing growth momentum

Oslo, 19 August 2025: In the second quarter, Scatec delivered solid financial results and achieved several strategic milestones, reinforcing its position as a leading provider of renewable energy i...

How does Scatec's performance compare to other renewable energy peers operating in high‑growth markets, and what does this imply for market share and competitive positioning? What guidance or outlook does Scatec provide for Q3 and full‑year 2025, especially regarding cash flow, capex, and new project pipelines? How will the 51% revenue growth and 19% EBITDA increase affect Scatec's valuation multiples and target price?

Symbol: SCATC

21 days ago

Read more globenewswire

Woodside Energy releases 2025 half-year results

PERTH, Australia--(BUSINESS WIRE)--Strong global portfolio delivers value and growth for Woodside Energy.

Symbol: WDS

22 days ago

CSL announces rise in full year net profit

Major strategic initiatives, including demerger, to transform CSL MELBOURNE, Aug. 19, 2025 /PRNewswire/ -- Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3....

Could the positive earnings surprise lead to a short-term price rally, and what are the potential risks to that momentum? What is the expected impact of the 17% net profit increase on CSL's valuation relative to its peers in the biotherapeutics sector? How will the announced demerger and strategic initiatives affect CSL's future earnings and cash flow?

Symbol: CSL

22 days ago

CSL announces rise in full year net profit

Major strategic initiatives, including demerger, to transform CSL MELBOURNE, Aug. 18, 2025 /PRNewswire/ -- Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3....

Will the profit growth translate into higher dividend payouts or share buyback activity, and how might that impact the stock's total return? What are the valuation implications of the 17% net profit increase on a constant currency basis relative to peers in the biotherapeutics sector? How will the announced demerger and other strategic initiatives affect CSL's earnings guidance for the next fiscal year?

Symbol: CSL

22 days ago

Agora, Inc. Reports Second Quarter 2025 Financial Results

SANTA CLARA, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Agora, Inc. (NASDAQ: API) (the “Company”), a pioneer and leader in conversational AI and real-time engagement technology, today announced it...

Are there any notable changes in operating margins, cash flow, or capital allocation that could influence the stock’s risk/reward profile? What guidance or outlook did Agora, Inc. provide for Q3 2025 and the full year, and how does it compare to market expectations? How will the reported Q2 2025 earnings and revenue growth affect API's valuation and price momentum?

Symbol: API

22 days ago

Read more globenewswire